In Friday’s Wall Street session, Amicus Therapeutics Inc (NASDAQ:FOLD) shares traded at $5.73, up 5.64% from the previous session.
FOLD stock price is now 2.25 away from the 50-day moving average and May 01 BMO away from the 200-day moving average. The market capitalization of the company currently stands at $1.74B.
With the price target reduced from $17 to $12, Morgan Stanley Downgraded its rating from Overweight to Equal-Weight for Amicus Therapeutics Inc (NASDAQ: FOLD). On September 06, 2024, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘Wells Fargo’ rates the stock as ‘Overweight’
In other news, Campbell Bradley L, President and CEO sold 400 shares of the company’s stock on Feb 19 ’25. The stock was sold for $4,000 at an average price of $10.00. Upon completion of the transaction, the President and CEO now directly owns 1,150,657 shares in the company, valued at $6.59 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 19 ’25, Director BRADLEY CAMPBELL bought 400 shares of the business’s stock. A total of $3,940 was incurred on buying the stock at an average price of $9.85. A total of 3.51% of the company’s stock is owned by insiders.
During the past 12 months, Amicus Therapeutics Inc has had a low of $5.72 and a high of $12.65. As of last week, the company has a debt-to-equity ratio of 2.47, a current ratio of 3.55, and a quick ratio of 34.45. The fifty day moving average price for FOLD is $6.4078 and a two-hundred day moving average price translates $9.0508 for the stock.
The latest earnings results from Amicus Therapeutics Inc (NASDAQ: FOLD) was released for 2025-03-31. The net profit margin was -5.41% and return on equity was -18.12% for FOLD.
